Torre Carla, Guerreiro José, de Oliveira Martins Sofia, Raposo João Filipe, Martins Ana Paula, Leufkens Hubert
Centre for Health Evaluation & Research (CEFAR), National Association of Pharmacies, Lisboa, Portugal; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal.
Centre for Health Evaluation & Research (CEFAR), National Association of Pharmacies, Lisboa, Portugal.
Prim Care Diabetes. 2015 Dec;9(6):482-9. doi: 10.1016/j.pcd.2015.03.009. Epub 2015 Apr 21.
To compare the temporal trends in the consumption patterns of glucose lowering drugs (GLD) between Portugal and the Netherlands from 2004 to 2013 and to examine possible reasons behind the cross-national variation found.
All GLD (ATC pharmacological subgroup A10B) were selected for analysis. Consumption data were obtained for the 10-year period. Portuguese and Dutch drug estimates were obtained from nationwide databases.
The consumption of GLD increased in Portugal from 52.9 defined daily dose per 1000 inhabitants per day (DHD) in 2004 to 70.0 DHD in 2013 and in the Netherlands from 44.9 DHD in 2004 to 50.7 DHD in 2013. In Portugal, the use of fixed-dose combinations, especially with dipeptidyl peptidase-4 inhibitors (DPP-4) increased remarkably and in 2013 represented almost a quarter of total GLD consumption. In the Netherlands, the use of combinations was residual.
The consumption of GLD rose over the 10-year period in both countries. However, Portuguese overall consumption and costs of GLD were higher. The differentially rapid uptake of DPP-4 inhibitors in Portugal was the main driver of the cost difference.
比较2004年至2013年葡萄牙和荷兰降糖药物（GLD）消费模式的时间趋势，并探究所发现的跨国差异背后的可能原因。
选取所有降糖药物（ATC药理学亚组A10B）进行分析。获取了10年期间的消费数据。葡萄牙和荷兰的药物估计数据来自全国性数据库。
葡萄牙的降糖药物消费量从2004年的每1000居民每日52.9限定日剂量（DHD）增至2013年的70.0 DHD，荷兰则从2004年的44.9 DHD增至2013年的50.7 DHD。在葡萄牙，固定剂量复方制剂的使用显著增加，尤其是与二肽基肽酶-4抑制剂（DPP-4）联用的制剂，2013年其用量几乎占降糖药物总消费量的四分之一。在荷兰，复方制剂的使用量很少。
两国在这10年期间降糖药物的消费量均有所上升。然而，葡萄牙降糖药物的总体消费量和成本更高。葡萄牙对DPP-4抑制剂的不同程度的快速采用是成本差异的主要驱动因素。
